Autophagy begins when a double-membraned vesicle, the autophagosome, engulfs cytoplasmic cargo and delivers it to the lysosome for degradation. The process is orchestrated by a cascade of autophagy-related genes, or ATG proteins, including Atg5, Atg7, and Atg12, which conjugate lipid to LC3/GABARAP proteins to build the vesicle. Upstream, two nutrient sensors act as master switches: mTOR, which suppresses autophagy when nutrients are plentiful, and AMPK, which triggers it through direct phosphorylation of the ULK1 complex when energy runs low. Sirtuin 1 adds another layer of control by deacetylating autophagy components. In most tissues this system is a survival mechanism; in the hypothalamus, the review contends, it has been co-opted into the circuitry of appetite itself.

The arcuate nucleus contains two opposing neuronal populations that sit at the heart of energy balance. Pro-opiomelanocortin, or POMC, neurons produce alpha-melanocyte-stimulating hormone, a signal that suppresses food intake and raises energy expenditure through the central melanocortin system. Agouti-related peptide, or AgRP, neurons do the opposite: they release AgRP and neuropeptide Y, powerful orexigenic signals that ramp up during fasting and drive feeding. According to the review, autophagy pushes these two populations in opposite directions, and understanding that divergence is essential to any therapeutic logic.

In POMC neurons, autophagy is portrayed as a guardian of metabolic health. Experiments in which autophagy genes were deleted from POMC cells showed impaired lipolysis in peripheral fat tissue, disrupted alpha-MSH production, and diminished leptin and insulin responsiveness. Work by Kaushik and colleagues published in EMBO Reports in 2012 demonstrated that losing autophagy in POMC neurons impairs fat breakdown, while a study in Cell Metabolism by Coupé and colleagues found that autophagy-deficient POMC neurons fail to extend axons properly during development, causing lasting metabolic dysregulation. An ATF4-ATG5 signaling axis has also been implicated in regulating obesity through these neurons. Disrupting the process, in short, predisposes animals to hyperphagia, leptin resistance, and the metabolic dysfunction that accompanies obesity.

The story in AgRP neurons is nearly inverted. Here, autophagy appears to promote feeding and energy conservation: it maintains AgRP expression, integrates ghrelin signals from the stomach, and participates in sensing circulating fatty acids. The landmark study by Kaushik and colleagues in Cell Metabolism in 2011 showed that autophagy in AgRP neurons regulates food intake and energy balance, and later work by Chen and colleagues in 2023 revealed that nutrient-sensing AgRP neurons can even relay control of liver autophagy during energy deprivation — a striking example of central-to-peripheral command. Consistent with this picture, inhibiting autophagy in AgRP neurons alleviates diet-induced obesity in mice, suggesting that damping down the hunger program could, in principle, be protective.

Yet the review is candid about contradictions in the literature, and this critical appraisal is arguably its most valuable contribution. Deleting Atg12 from POMC neurons exacerbates diet-induced obesity, but deleting Atg5 does not — an unsettling discrepancy given that both genes participate in the same LC3 lipidation cascade. The authors attribute such inconsistencies to several variables: the specific autophagy gene targeted, whether the deletion occurs during development or in adulthood, the dietary paradigms used, and a widespread reliance on static markers such as LC3 puncta or p62 aggregates, which reflect the accumulation of autophagosomes rather than the true rate of autophagic flux. The fourth-edition guidelines for monitoring autophagy emphasize exactly this distinction, and many hypothalamic studies fall short of the dynamic measurements needed to resolve it.

The framework also extends beyond the arcuate nucleus. The review situates POMC and AgRP autophagy within broader hypothalamic and extra-hypothalamic networks, including newly identified basonuclin 2 neurons that acutely suppress food intake when activated by leptin, steroidogenic factor 1 neurons of the ventromedial hypothalamus — where defective autophagy perturbs the metabolic response to fasting and causes mitochondrial dysfunction — and downstream paraventricular pathways projecting to the brainstem, liver, and adipose tissue. Glial cells and tanycytes, the specialized ependymal cells lining the third ventricle, add further complexity: tanycytic TSPO inhibition has been shown to induce lipophagy and improve energy balance, and adenosine transmission from tanycytes to AgRP neurons regulates energy homeostasis. Obesity-induced blood-brain barrier dysfunction may further modulate how circulating nutrients and hormones reach these circuits.

A particularly intriguing thread involves chaperone-mediated autophagy, or CMA, a distinct form of lysosomal degradation in which the chaperone Hsc70 delivers specific proteins across the lysosomal membrane through the LAMP2A receptor. Studies in POMC-like neurons in vitro show that palmitic and stearic acids — saturated fatty acids abundant in Western diets — inhibit CMA, and lipid excess has been shown to impair CMA in the whole hypothalamus. Because CMA degrades lipid droplet-associated proteins and thereby facilitates lipolysis, its suppression by saturated fat could plausibly link dietary lipid exposure, hypothalamic proteostasis, and insulin responsiveness. Recent work even suggests that central activation of CMA reduces appetite by fine-tuning hypothalamic amino acid pools. The review stresses, however, that direct evidence for this pathway in vivo remains limited, and it should be treated as a hypothesis rather than a mechanism.

The translational picture is equally restrained. No study has yet demonstrated altered autophagic flux in human POMC or AgRP neurons, although a comprehensive spatio-cellular map of the human hypothalamus published in 2025 and region-specific transcriptomic data from macaques now make such investigation conceivable. Existing obesity therapies that touch the hypothalamus — setmelanotide for acquired hypothalamic obesity, GLP-1 receptor agonists, and metformin’s effects on hypothalamic inflammation — were not designed around autophagy. The review concludes that future therapies will likely require pathway-biased, neuron-type-specific, and circuit-aware modulation rather than global activation or inhibition of autophagy, since wholesale suppression could harm POMC neurons while selective inhibition of AgRP autophagy might help. A drug that broadly drenches the hypothalamus in an autophagy modifier would almost certainly deliver both benefit and harm to adjacent cell types.

For a field long dominated by accounts of hypothalamic inflammation and endoplasmic reticulum stress in obesity, the reframing is provocative: the same intracellular recycling pathway that keeps neurons alive may also calibrate the signals that make organisms hungry or satisfied. The authors acknowledge that the framework is best viewed as a mechanistic and translational research program, not a clinical endpoint. But with human hypothalamic atlases, flux reporters, and single-cell tracing of POMC subtypes now available, the tools to test whether autophagic flux in appetite neurons is genuinely altered in human obesity are, for the first time, within reach.

Subject of Research: The role of autophagy in hypothalamic POMC and AgRP neurons in regulating appetite and obesity

Article Title: Autophagy in hypothalamic POMC and AgRP neurons: mechanisms and therapeutic implications for obesity

Article References: Jing, D., Dai, R., Peng, S., Zeng, L., & Cai, J. (2026). Autophagy in hypothalamic POMC and AgRP neurons: mechanisms and therapeutic implications for obesity. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02223-y

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02223-y

Keywords: autophagy, hypothalamus, POMC neurons, AgRP neurons, obesity, leptin resistance, arcuate nucleus, chaperone-mediated autophagy, appetite regulation, Atg genes, energy homeostasis, melanocortin system

The headline finding is a story of explosive growth followed by a plateau. Annual output rose from a single publication in 1995 to 91 in 2025, a compound annual growth rate of 16.2 percent, but the trajectory was anything but smooth. Research activity peaked in 2014 with 109 publications, fluctuated thereafter and settled into an average of 87.2 publications per year between 2015 and 2025, compared with just 37.3 annually during 1995 to 2004. Original articles dominated the corpus, accounting for 1658 publications or 76.69 percent, with reviews contributing another 433 papers, a proportion the author interprets as a sign that the field has accumulated enough evidence to require synthesis and clearer conceptual organisation.

Geographically, the field is strikingly concentrated. Affiliation strings resolved to 76 countries, yet the United States alone produced 741 publications, 34.27 percent of the corpus, and accumulated 83,759 citations, far ahead of any other nation. China ranked second with 255 publications, followed by Japan, Spain, Germany, Brazil, the United Kingdom, France, Australia and Canada. The collaboration network reinforced this picture of a hub-and-spoke world: the United States occupied the largest node and the strongest total link strength in the co-authorship map, maintaining collaborative ties with China, Japan, Canada, Germany, France, Spain, Australia, Italy and Brazil. Notably, the United Kingdom led the top ten in international collaboration, with 57.43 percent of its publications involving at least two countries, while American output was more domestically anchored at just under 30 percent.

Institutionally, the landscape is anchored by a handful of elite biomedical centres. After targeted harmonisation of affiliation variants, Harvard Medical School emerged as the most productive institution with 56 publications and the largest corpus-specific h-index of 43. Beth Israel Deaconess Medical Center, despite slightly fewer publications, recorded the highest total citations at 12,239 and an extraordinary 254.98 citations per publication, a figure that reflects its role in foundational leptin physiology work. INSERM, the Universidade de São Paulo, UT Southwestern Medical Center, the University of Iowa, CIBEROBN, the University of Michigan, the University of Washington and the University of Florida completed the top ten. At the author level, Brazilian researchers Lisboa P.C. and Moura E.G. led productivity with 33 and 31 papers respectively, while Kamal Rahmouni of the obesity-hypertension field posted the highest citation impact among prolific authors.

The journal analysis reveals a field that sprawls across disciplinary boundaries. Endocrinology published the most articles with 73, followed by Diabetes with 58 and the International Journal of Obesity with 47. PLOS One, the American Journal of Physiology titles, the International Journal of Molecular Sciences, Cell Metabolism, Molecular Metabolism and Frontiers in Endocrinology rounded out the top ten. Cell Metabolism boasted the highest citations per publication at 178.60, while Diabetes accumulated the greatest total citations at 9849. This dispersal, the study notes, mirrors the multidisciplinary nature of leptin resistance research itself, spanning endocrinology, neuroscience, molecular biology, physiology and cardiometabolic medicine.

The citation analysis doubles as a history of the field’s intellectual core. The most cited paper remains the 2001 Nature study by Cowley and colleagues demonstrating that leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus, with 2052 citations. Close behind are Frederich and colleagues’ 1995 Nature Medicine paper providing evidence for diet-induced resistance to leptin action, with 1533 citations, and Kalra and colleagues’ 1999 Endocrine Reviews synthesis of hypothalamic appetite regulation, with 1457. Other heavily cited works include Caro and colleagues’ 1996 Lancet report of a decreased cerebrospinal-fluid-to-serum leptin ratio in obesity, Zabolotny and colleagues’ identification of PTP1B as a leptin signal regulator, Milanski and colleagues on hypothalamic TLR4 inflammation, and Ozcan and colleagues on endoplasmic reticulum stress as a driver of leptin resistance.

Beyond the central signalling story, the most-cited corpus stretches into the wider metabolic periphery. Highly cited papers on adipose tissue as an endocrine organ, gut microbiota responses in leptin-resistant mice, low-grade inflammation and type 2 diabetes, and obesity-associated hypertension show that leptin resistance has long been studied not as an isolated appetite defect but as a node in a broader cardiometabolic network. A year-normalised citation ratio in the analysis highlights how recent reviews, such as a 2021 Frontiers in Endocrinology overview of leptin’s clinical implications, have accumulated citations at an exceptional pace, with 947 citations and a normalised ratio of 24.90 against same-year peers.

The study’s visualisation component delivers perhaps its most quotable insight: the field’s vocabulary has visibly shifted. Using VOSviewer term co-occurrence mapping on titles and abstracts, with a threshold of 50 occurrences that admitted 257 of 28,255 terms, the analysis identified three thematic clusters. The first, clinical metabolic dysfunction and cardiometabolic risk, groups terms such as leptin level, insulin resistance, glucose, diabetes, metabolic syndrome, body mass index, inflammation, adiponectin, hypertension and cardiovascular disease. The second captures hypothalamic leptin signalling, appetite control and energy homeostasis, featuring hypothalamus, food intake, body weight, energy expenditure, neuropeptide, melanocortin, POMC neuron, arcuate nucleus, leptin receptor, diet-induced obesity and STAT3. The third links body weight regulation with developmental and experimental models, including rat, pregnancy, offspring, lactation and chow, pointing to a substantial literature on early-life nutritional programming of later metabolic dysfunction.

An overlay visualisation colouring each term by its average publication year makes the temporal evolution legible at a glance. Early blue-era terms include rat, serum leptin, leptin concentration, body mass index, neuropeptide and mRNA, the vocabulary of the field’s foundational decades. Intermediate green terms such as weight, diet, food intake, hypothalamus, mouse and insulin resistance mark the mechanistic middle period. The yellow frontier is dominated by inflammation, disease, diabetes, oxidative stress, pathogenesis, progression, risk, patient, hypertension, cardiovascular disease, adipokine, high-fat diet, molecular mechanism, glucose homeostasis and pathway. The author is careful to frame this as descriptive evidence of broadening vocabulary rather than proof of a causal transition, noting that lexical fashion and nomenclature changes, including the shift from NAFLD to MAFLD and MASLD, can shift average publication years independently of any genuine change in research focus.

The analysis also carries methodological rigour worth noting. The search strategy was validated by screening the 100 most-cited records for relevance, with irrelevant or partially related records below 5 percent, and by comparing retrieved output against the manually verified Scopus profiles of the top 20 most productive authors, achieving an intraclass correlation coefficient of 0.964. A boundary sensitivity rerun showed that including the broader expressions leptin sensitivity and leptin responsiveness added 281 publications, 13 percent of the corpus, all beyond the narrower query’s yield. Limitations are candidly acknowledged: reliance on a single database, citation counts that reflect age and visibility as much as quality, metadata disambiguation errors that may split or merge author identities, and an English-language search strategy that may miss relevant non-English work, even though the retrieved corpus included 164 non-English records. The paper closes by flagging the field’s most urgent gaps, including the absence of a widely accepted clinical definition of leptin resistance, the need to translate animal-model mechanisms into human metabolic outcomes, and the desirability of broader geographic participation in a literature still dominated by high-output nations.

Subject of Research: Bibliometric mapping of global research on leptin resistance and obesity-related metabolic dysfunction from 1995 to 2025

Article Title: Global Research Landscape on Leptin Resistance and Obesity‐Related Metabolic Dysfunction: Trends, Networks and Visualisation Analysis (1995–2025)

Article References: Zyoud, S. H. (2026). Global Research Landscape on Leptin Resistance and Obesity‐Related Metabolic Dysfunction: Trends, Networks and Visualisation Analysis (1995–2025). Endocrinology, Diabetes & Metabolism, 9(5), Article e70330. https://doi.org/10.1002/edm2.70330

Image Credits: AI Generated

DOI: 10.1002/edm2.70330

Keywords: leptin resistance, obesity, metabolic dysfunction, bibliometrics, hypothalamus, insulin resistance, inflammation, cardiometabolic risk, Scopus, VOSviewer, gut microbiota, type 2 diabetes